Home › Research › What the research found › Every row
Every row of the evidence table
One row per finding: what was tested, which way the result went, and how the study was built. The answer by area, and where the studies disagree, are on the main page.
Every row
Filter
Showing 2 of 382 rows. One row per study per exposure: a study that tested two different things appears twice, once for each.
Scroll the table sideways to see every column.
| Exposure | Question | Direction | Outcome measured | Design | People | Effect size, as the source reported it | Source |
|---|---|---|---|---|---|---|---|
| Cost-effectiveness of multidomain prevention programme Care, carers and services | Prevention |
Benefit
whyDirection is for value for money: the intervention was modelled as dominant, saving JPY 452,826 per person and adding 0.08 QALYs over 35 years, with sensitivity analyses described as confirming robustness. A model extrapolating an 18-month trial. |
Lifetime costs and QALYs of the J-MINT multidomain intervention versus usual care (35-year model) | modelling study | not stated | Over 35 years, J-MINT was projected to achieve cost savings of JPY 452,826 per person and a gain of 0.08 QALYs |
The journal of prevention of Alzheimer's disease
2026 ✓ Peer-reviewed PMID 41478834 |
| Health-system and payment model Care, carers and services | Treatment |
Benefit
whyDirection is for the benefit redesign: projected out-of-pocket drug spending fell 55% ($56 to $25) for low-income-subsidy beneficiaries and 25% ($772 to $576) for others, with larger reductions for people with 6-8 comorbidities. |
Simulated annual out-of-pocket drug spending for Medicare beneficiaries with dementia under the 2025 Part D cost-sharing rules | modelling study | 1,677 | we project average annual OOP drug expenditures among LIS beneficiaries with dementia to decrease from $56 to $25-representing a $31, or 55%, reduction. In contrast, among non-LIS beneficiaries, average OOP drug expenditures is projected to decrease from $772 to $576, a $196, or 25% reduction |
Value in Health
2025 ✓ Peer-reviewed PMID 39880200 |